Contact Us

Yes. G6PD rescue experiments are well-established for PPP and redox biology research: • Construct design: use a codon-modified G6PD sequence with a small C-terminal tag (FLAG, HA). G6PD has NADP+ binding sites, substrate binding pocket, and dimer/tetramer interface — preserve all elements. • Catalytically-dead rescue: substrate-binding pocket mutations abolish dehydrogenase activity and serve as the standard specificity control. • Deficiency variant rescue: G6PD A- (Class III deficiency), Mediterranean (Class II), Canton, Kaiping, and other deficiency variants for disease genotype-function studies. • Functional readout: rescue should restore NADPH generation and PPP flux measured by ¹³C-glucose tracing. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on the experimental question. FKBP15 (FK506-binding protein 15, WAFL) is a less-characterized member of the FKBP family of peptidyl-prolyl cis-trans isomerases. The Knockout line is appropriate for asking whether FKBP15 is required for predicted activities — the FKBP family includes immunophilins (FKBP12, FKBP25, FKBP38, FKBP52) that bind immunosuppressants tacrolimus and rapamycin, with diverse roles in protein folding, trafficking, and signaling; FKBP15's specific functions remain incompletely characterized. Overexpression is useful for studying FKBP15 in heterologous expression contexts. For FKBP family research, the EDITGENE FKBP15 Knockout in HAP1 provides a clean genetic background for characterizing FKBP15-specific functions. Other FKBP family member expression analysis aids interpretation. Rescue with wild-type FKBP15 is the standard specificity control. The knockout is valuable for FKBP family discovery research and substrate identification.

Yes, and rescue experiments are essential for substrate characterization: • Construct design: use a codon-modified FKBP15 sequence with a small C-terminal tag (FLAG, HA). FKBP15 has FKBP-type PPIase domain and additional functional regions — preserve domain architecture. • PPIase-dead rescue: catalytic residue mutations in the FKBP PPIase domain abolish prolyl isomerase activity. • Discovery-oriented rescue: parallel wild-type rescue during phenotypic characterization distinguishes FKBP15-dependent phenotypes. • Functional readout: rescue should restore phenotypes identified during knockout characterization. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying GLP1R's role as the GLP-1 receptor or modeling its emerging functions in respiratory biology and inflammation. The Knockout line is the standard tool for asking whether GLP1R is required for GLP-1-induced signaling — GLP1R is a Gs-coupled class B GPCR activated by GLP-1 (and GLP-1-mimetic drugs), driving cAMP-PKA signaling for insulin secretion (canonical β-cell function) and weight loss/satiety effects (CNS); GLP1R has emerging non-pancreatic functions in lung, kidney, and immune cells. Overexpression is useful for studying GLP1R in heterologous expression contexts. For respiratory biology research, the EDITGENE GLP1R Knockout in BEAS-2B is highly relevant — BEAS-2B is a normal human bronchial epithelial cell line, and GLP1R has emerged as expressed in respiratory epithelium with implications for asthma and COPD biology. Rescue with wild-type or signaling-deficient GLP1R enables structure-function studies. The knockout is a critical specificity control for GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy, FDA-approved for T2D and obesity), tirzepatide (Mounjaro/Zepbound, dual GIP/GLP-1 agonist), liraglutide, exenatide — and emerging GLP1R-targeted respiratory disease therapeutics.

Yes. GLP1R rescue experiments are well-established for GLP-1 pharmacology research: • Construct design: use a codon-modified GLP1R sequence with a small intracellular C-terminal tag (FLAG, HA). GLP1R is a class B GPCR with large extracellular ligand-binding domain and seven-transmembrane region — preserve all elements. • Signaling-deficient rescue: DRY motif or specific intracellular loop mutations disrupt Gs-coupling. • Biased signaling studies: specific mutations can generate G-protein-biased or β-arrestin-biased GLP1R variants for biased agonism research. • Functional readout: rescue should restore semaglutide/tirzepatide-induced cAMP elevation and PKA-dependent downstream signaling. BEAS-2B-specific considerations: • BEAS-2B is a SV40-immortalized normal human bronchial epithelial cell line — widely used for respiratory epithelial biology, environmental toxicology, and airway disease research. • Lentiviral transduction is supported but may require optimization compared to standard transformed cell lines. • BEAS-2B's normal bronchial epithelial origin makes it relevant for non-cancer respiratory studies.

The choice depends on whether you are studying B2M (β-2-microglobulin)'s role as the essential MHC class I light chain or modeling its applications in checkpoint inhibitor resistance and universal allogeneic CAR-T platforms. The Knockout line is the standard tool for asking whether B2M is required for these processes — B2M is the non-polymorphic light chain of all MHC class I molecules (HLA-A, HLA-B, HLA-C); B2M is required for MHC class I surface expression — B2M loss eliminates virtually all MHC I surface presentation, enabling immune evasion in cancer and serving as a strategy for universal allogeneic cell therapy platforms. Overexpression is useful for studying B2M gain-of-function effects. For cancer immunology research, the EDITGENE B2M Knockout in HEK293T is uniquely valuable — HEK293T's very high transfection efficiency supports systematic structure-function studies. This product complements the parallel B2M Knockouts in A-549 and A-375 (both also available) for cancer context-specific studies. Rescue with wild-type B2M is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐⭐ checkpoint inhibitor resistance research (B2M loss-of-function mutations are a major mechanism of acquired resistance to pembrolizumab/nivolumab/ipilimumab); ⭐⭐ universal CAR-T cell development (B2M KO eliminates HLA-class I to enable allogeneic 'off-the-shelf' CAR-T cells, used in CTX110/CTX120/CTX130 platforms); and emerging cancer immune evasion mechanism studies.

Yes. B2M rescue experiments are well-established for MHC I research: • Construct design: use a codon-modified B2M sequence with a small C-terminal tag (FLAG, HA, after the signal peptide). B2M is a small soluble light chain (~12 kDa) — preserve all elements. • MHC class I surface restoration: rescue with WT B2M should restore HLA-ABC surface expression measured by flow cytometry (anti-pan-HLA-I clone W6/32). • Universal CAR-T validation: WT B2M rescue restores allorecognition by host T cells — useful for verifying B2M-dependent HvG. • Functional readout: rescue should restore CD8+ T cell-mediated cytotoxicity in MHC I-restricted contexts. HEK293T transduces with very high efficiency and supports stable rescue line generation.

The choice depends on whether you are studying CCND1 (cyclin D1)'s role as the canonical G1 cyclin or modeling cyclin D1 amplification-driven cancers (especially mantle cell lymphoma) and CDK4/6 inhibitor pharmacology. The Knockout line is the standard tool for asking whether Cyclin D1 is required for these processes — CCND1/Cyclin D1 partners with CDK4 and CDK6 to phosphorylate RB1 at G1 transition, releasing E2F transcription factors; CCND1 is among the most clinically actionable oncogenes — t(11;14) translocation causing cyclin D1 overexpression is the defining feature of mantle cell lymphoma (MCL), and CCND1 amplification is common in breast, head and neck, esophageal cancers. Overexpression is useful for studying cyclin D1 amplification effects. For cancer biology research, the EDITGENE CCND1 Knockout in HEK293 is uniquely valuable — Cyclin D1 is the partner of CDK4/6 (the parallel CDK4 and CDK6 Knockouts in HEK293 are also available), and CCND1-CDK4/6 axis is the target of the FDA-approved breast cancer drugs palbociclib/ribociclib/abemaciclib. CCND2, CCND3 paralog expression analysis aids interpretation given partial functional overlap. Rescue with wild-type or T286A (GSK3β-resistant, stable) cyclin D1 enables cancer modeling. The knockout is a critical specificity tool for ⭐⭐⭐ palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Verzenio) (FDA-approved CDK4/6 inhibitors for HR+ breast cancer), and emerging cyclin D1 PROTACs/degraders.

Yes. CCND1 rescue experiments are well-established for breast cancer research: • Construct design: use a codon-modified CCND1 sequence with a small C-terminal tag (FLAG, HA). CCND1 has cyclin-box domain and C-terminal T286 GSK3β phosphorylation site — preserve all elements. • T286A stable rescue: T286A mutation in the GSK3β phosphorylation site prevents proteasomal degradation, generating stable cyclin D1 — useful for studying CCND1 amplification and MCL t(11;14) overexpression effects. • CDK4/6-binding-deficient rescue: cyclin-box mutations disrupt CDK4/6 partnership. • Functional readout: rescue should restore Cyclin D1-CDK4/6 kinase activity and palbociclib/ribociclib/abemaciclib sensitivity. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for CDK4/6 inhibitor research.

The choice depends on whether you are studying BMPR1B (ALK6)'s role as a type I BMP receptor or modeling its functions in cartilage biology and emerging cancer applications. The Knockout line is the standard tool for asking whether BMPR1B is required for BMP signaling — BMPR1B is a type I serine/threonine kinase receptor for BMPs (especially BMP2, BMP4, BMP7, GDF5) that, upon ligand binding, recruits type II receptor (BMPR2) and phosphorylates SMAD1/5/8 transcription factors. BMPR1B is critical for cartilage/skeletal development. Overexpression is useful for studying BMPR1B gain-of-function effects. For BMP signaling research, the EDITGENE BMPR1B Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic structure-function studies. This product complements the parallel BMPR1B Knockout in HAP1 (also available) for cross-background validation. BMPR1B mutations cause brachydactyly type A2 and acromesomelic dysplasia. Rescue with wild-type or kinase-dead BMPR1B enables structure-function studies. The knockout is valuable for studying BMP-SMAD signaling and emerging BMPR1B-targeted approaches.

Yes. BMPR1B rescue experiments are well-established for BMP signaling research: • Construct design: use a codon-modified BMPR1B sequence with a small intracellular C-terminal tag (FLAG, HA). BMPR1B has extracellular ligand-binding region, single transmembrane span, GS domain (type II receptor phosphorylation site), and intracellular kinase domain — preserve all elements. • Surface localization validation: confirm plasma membrane localization before BMP binding studies. • Kinase-dead rescue: K231R mutation in the ATP-binding lysine abolishes catalytic activity. • Constitutively-active rescue: Q203D mutation in the GS domain generates constitutively active BMPR1B. • Functional readout: rescue should restore BMP-induced phospho-SMAD1/5/8 signaling. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying CDK2's role as the canonical S-phase CDK or modeling emerging CDK2 inhibitor pharmacology for cancer therapy. The Knockout line is the standard tool for asking whether CDK2 is required for these processes — CDK2 partners with cyclin E (G1/S) and cyclin A (S-phase) to drive DNA replication and S-phase progression, phosphorylating RB1 (hyperphosphorylation), CDC6, and DNA replication factors; CDK2 has emerged as a cancer therapy target especially for CDK4/6 inhibitor-resistant breast cancer (Cyclin E1/CCNE1-amplified). Overexpression is useful for studying CDK2 gain-of-function effects. Important consideration: CDK2 and CDK1 have overlapping substrates — CDK2 deletion is tolerated in mice (compensated by CDK1) but creates synthetic vulnerabilities in CCNE1-amplified cancers. Rescue with wild-type or kinase-dead CDK2 is the standard specificity control. The knockout is a critical specificity tool for ⭐ tagtociclib (PF-07104091, CDK2-selective inhibitor in clinical development), BLU-222 (CDK2-selective inhibitor), INX-315, and emerging CDK2-selective inhibitors for CCNE1-amplified cancers (ovarian, breast, endometrial cancer).

Yes. CDK2 rescue experiments are well-established for emerging CDK2 drug research: • Construct design: use a codon-modified CDK2 sequence with a small C-terminal tag (FLAG, HA). CDK2 has the canonical CDK architecture (PSTAIRE, T-loop with T160 activation site) — preserve all elements. • Kinase-dead rescue: K33R mutation in the ATP-binding lysine abolishes catalytic activity. • Functional readout: rescue should restore Cyclin E/A-CDK2 kinase activity, phospho-RB1 hyperphosphorylation, and S-phase progression. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for emerging CDK2-selective drug development.

The choice depends on whether you are studying CD9 (tetraspanin TSPAN29)'s role as a classical tetraspanin or modeling its functions in cell-cell fusion, exosome biology, and cancer metastasis. The Knockout line is the standard tool for asking whether CD9 is required for these processes — CD9 is a four-transmembrane tetraspanin that organizes tetraspanin-enriched microdomains (TEMs) at the cell surface, associating with integrins, ADAMs, and other partners; CD9 is essential for sperm-egg fusion (CD9 is on the oocyte), platelet aggregation, and is a classical exosome surface marker. Overexpression is useful for studying CD9 in heterologous expression contexts. For tetraspanin and exosome research, the EDITGENE CD9 Knockout in HEK293 enables systematic study of tetraspanin biology. Other tetraspanin family member (CD81, CD63, CD151) expression analysis aids interpretation. Rescue with wild-type CD9 is the standard specificity control. The knockout is valuable for studying CD9-mediated cell-cell interactions, CD9 as an exosome marker (CD9-null exosomes can be used to study CD9-dependent vs CD9-independent exosome cargo and function), and emerging CD9-targeted therapeutics in cancer metastasis research.

Yes. CD9 rescue experiments require attention to tetraspanin architecture: • Construct design: use a codon-modified CD9 sequence with a small intracellular tag (FLAG, HA). CD9 is a four-transmembrane tetraspanin with two extracellular loops (EC1, EC2) and intracellular termini — preserve membrane topology. • Surface localization validation: confirm plasma membrane localization by cell surface staining before functional assays. • Partner-binding-deficient rescue: EC2 loop mutations disrupt specific tetraspanin partner interactions. • Functional readout: rescue should restore CD9-dependent tetraspanin-enriched microdomain organization. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.